BALAXI PHARMACEUTICALS LIMITED

Company Profile

BALAXI PHARMACEUTICALS LIMITED had its IPO on under the ticker symbol BALAXI.

The company operates in the sector and industry. BALAXI PHARMACEUTICALS LIMITED has a staff strength of 0 employees.

Stock update

Shares of BALAXI PHARMACEUTICALS LIMITED opened at 561.6 at the start of the last trading session i.e. 2023-05-28.

The stocks traded within a range of 561.6 - 572.25, and closed at 570.3.

This is a +1.56% increase from the previous day's closing price.

A total volume of 2,071 shares were traded at the close of the day’s session.

In the last one week, shares of BALAXI PHARMACEUTICALS LIMITED have increased by +4.14%.

BALAXI PHARMACEUTICALS LIMITED's Key Ratios

BALAXI PHARMACEUTICALS LIMITED has a market cap of 0, indicating a price to book ratio of and a price to sales ratio of .

In the last 12-months BALAXI PHARMACEUTICALS LIMITED’s revenue was 0 with a gross profit of 0 and an EBITDA of 0. The EBITDA ratio measures BALAXI PHARMACEUTICALS LIMITED's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, BALAXI PHARMACEUTICALS LIMITED’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q0.33333333333333, BALAXI PHARMACEUTICALS LIMITED’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

BALAXI PHARMACEUTICALS LIMITED’s PE and PEG Ratio

Forward PE

Trailing PE

PEG

Its diluted EPS in the last 12-months stands at per share while it has a forward price to earnings multiple of and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BALAXI PHARMACEUTICALS LIMITED’s profitability.

BALAXI PHARMACEUTICALS LIMITED stock is trading at a EV to sales ratio of and a EV to EBITDA ratio of . Its price to sales ratio in the trailing 12-months stood at .

BALAXI PHARMACEUTICALS LIMITED stock pays annual dividends of per share, indicating a yield of and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

0

Total Liabilities

0

Operating Cash Flow

0

Capital Expenditure

0

Dividend Payout Ratio

0%

BALAXI PHARMACEUTICALS LIMITED ended 1970 with 0 in total assets and 0 in total liabilities. Its intangible assets were valued at 0 while shareholder equity stood at 0.

BALAXI PHARMACEUTICALS LIMITED ended 1970 with 0 in deferred long-term liabilities, 0 in other current liabilities, in common stock, 0 in retained earnings and 0 in goodwill. Its cash balance stood at 0 and cash and short-term investments were 0. The company’s total short-term debt was 0 while long-term debt stood at 0.

BALAXI PHARMACEUTICALS LIMITED’s total current assets stands at 0 while long-term investments were 0 and short-term investments were 0. Its net receivables were 0 compared to accounts payable of 0 and inventory worth 0.

In 1970, BALAXI PHARMACEUTICALS LIMITED's operating cash flow was 0 while its capital expenditure stood at 0.

Comparatively, BALAXI PHARMACEUTICALS LIMITED paid 0 in dividends in 1970.

Other key metrics

Current Trading Price

570.3

52-Week High

52-Week Low

Analyst Target Price

BALAXI PHARMACEUTICALS LIMITED stock is currently trading at 570.3 per share. It touched a 52-week high of and a 52-week low of . Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was 544.78 and 200-day moving average was 561.41 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.